Sleep-disordered breathing in Australian children with Prader-Willi syndrome following initiation of growth hormone therapy

Daan Caudri, Gillian M Nixon, Aleisha Nielsen, Linda Mai, Claire R Hafekost, Nitin Kapur, Antony R Lafferty, and Catherine S Choong

1 Telethon Kids Institute, The Centre for Child Health Research, The University of Western Australia, 2 Respiratory and Sleep Medicine, Perth Children’s Hospital, 3 Faculty of Medicine and Health Sciences, The University of Western Australia, 4 School of Physiotherapy and Exercise Science, Curtin University, 5 Melbourne Children’s Sleep Centre, 6 Department of Paediatrics, Logan Hospital, Brisbane, Queensland, 7 Respiratory and Sleep Medicine, Queensland Children’s Hospital, 8 School of Clinical Medicine, University of Queensland, 27 Department of Paediatric Endocrinology & Diabetes, Monash Children’s Hospital, 22 Department of Paediatrics, Monash University, Melbourne, Victoria, 23 Respiratory and Sleep Medicine, Queensland Children’s Hospital, 24 School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, 17 Department of Paediatric Endocrinology and Diabetes, John Hunter Children’s Hospital, Newcastle, 18 School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, 19 Respiratory and Sleep Department, 25 Endocrinology and Diabetes Department, Women’s and Children’s Hospital, 16 Sydney Children’s Hospital Westmead, 10 Woolcock Institute of Medical Research, Sydney University, 15 Discipline of Child and Adolescent Health, The University of Sydney, 21 School of Women’s and Children’s Health, The University of New South Wales, Sydney, Departments of 13 Sleep Medicine, 12 Endocrinology, Sydney Children’s Hospital Randwick, 14 The Sydney Children’s Hospitals Network, Westmead, 17 Department of Paediatric Endocrinology and Diabetes, John Hunter Children’s Hospital, Newcastle, 13 School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, 11 Respiratory and Sleep Department, 20 Endocrinology and Diabetes Department, Women’s and Children’s Hospital, 19 Endocrinology, Sydney Children’s Hospital, 26 Medical School, Australian National University, Canberra, Australia, 27 Department of Paediatric Pulmonology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands

Aim: In children with Prader-Willi syndrome (PWS), growth hormone (GH) improves height and body composition; however, may be associated with worsening sleep-disordered breathing (SDB). Some studies have reported less SDB after GH initiation, but follow-up with polysomnography is still advised in most clinical guidelines.

Methods: This retrospective, multicentre study, included children with PWS treated with GH at seven PWS treatment centres in Australia over the last 18 years. A paired analysis comparing polysomnographic measures of central and obstructive SDB in the same child, before and after GH initiation was performed with Wilcoxon signed-rank test. The proportion of children who developed moderate/severe obstructive sleep apnoea (OSA) was calculated with their binomial confidence intervals.

Results: We included 112 patients with available paired data. The median age at start of GH was 1.9 years (range 0.1–13.5 years). Median obstructive apnoea hypopnoea index (AHI) at baseline was 0.43/h (range 0–32.9); 35% had an obstructive AHI above 1.0/h. Follow-up polysomnography within 2 years after the start of GH was available in 94 children who did not receive OSA treatment. After GH initiation, there was no change in central AHI. The median obstructive AHI did not increase significantly (P = 0.13), but 12 children (13%, CI95% 7–21%) developed moderate/severe OSA, with clinical management implications.

Conclusions: Our findings of a worsening of OSA severity in 13% of children with PWS support current advice to perform polysomnography after GH initiation. Early identification of worsening OSA may prevent severe sequelae in a subgroup of children.

Key words: central sleep apnoea; growth hormone; obstructive sleep apnoea; polysomnography; Prader-Willi syndrome; sleep-disordered breathing.

What is already known on this topic

1 Growth hormone improves height and body composition in children with Prader-Willi syndrome but has been linked with worsening sleep-disordered breathing.

2 Previous studies were unable to show significant worsening of obstructive sleep apnoea after initiation of growth hormone using polysomnography, although severe worsening of

What this paper adds

1 In line with previous studies, we found an increase in moderate/severe obstructive sleep apnoea in a subgroup of patients after initiation of growth hormone.

2 This led to changes in clinical management in 13% of our study population.

Correspondence: Dr Daan Caudri, Department of Paediatric Pulmonology, Erasmus MC - Sophia Children’s Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands. Fax: +31 10 703 98 50; email: d.caudri@erasmusmc.nl

Conflict of interest: None of the authors have a conflict of interest to declare in relationship to this manuscript.

Accepted for publication 15 July 2021.
Prader-Willi syndrome (PWS) is a rare multisystem disorder affecting approximately 1 in 15 000 live births arising from the lack of gene expression from the paternally inherited 15q11-q13 region on chromosome 15. The cardinal features of PWS are muscular hypotonia, hypothalamic dysfunction, psychomotor delay, short stature and hyperphagia that can lead to severe obesity after the age of 2–4 years. Life expectancy in previously published cohorts is shortened such that 13–20% are deceased by 35 years. Recent improvement in survival is attributed to earlier diagnosis and therapeutic intervention, particularly delaying or preventing the onset of obesity. Respiratory and sleep disorders including hyperventilation, decreased pulmonary function, obstructive and central sleep apnoea and reduced response to hypoxia and hypercapnia are more common in children with PWS than in the general population. Respiratory-related causes have been identified as the most common cause of death in children with PWS and may contribute to the increased risk of sudden death in patients with PWS.

Growth hormone (GH) treatment in PWS results in a significant increase in height, improvement in body composition, reduced incidence of type 2 diabetes mellitus and enhanced mental and motor development. In Australia, these benefits have led to approval of subsidised GH treatment in all children with PWS under the Commonwealth Pharmaceutical Benefits Scheme since 2009. A major concern of GH treatment in children with PWS, however, has been the potential association with sudden unexpected death. It has been postulated that this is due to worsening of obstructive sleep apnoea (OSA) as a result of GH therapy. Indeed, the growth of lymphoid tissue and/or pharyngeal wall thickening has been observed in patients with endogenous production of excess GH. The association between GH therapy and sudden death remains controversial as sudden death in PWS has been described well before the introduction of GH. Others have reported an apparent association, noting in one study that death and noted this most often occurred during the first 9 months following the initiation of GH.

The higher prevalence of both obstructive and central sleep disturbed breathing in children with PWS compared to the general paediatric population is well documented however, the effect of GH treatment on sleep-disordered breathing in PWS remains controversial. Three previous studies reported no significant increase in obstructive events, although they all noted worsening in a small subgroup of patients. A more recent study by Berini et al. reported significant worsening of obstructive events after GH initiation, but this effect was outweighed by the improvement in central breathing events, causing an overall improvement in total apnoea hypopnoea index (AHI) after GH. Most, but not all authors have advised a cautious approach with standard screening using polysomnography (PSG) in the follow-up 6 months after the initiation of GH therapy.

Current guidelines advise sleep studies before initiation and within 6 months after start of GH therapy in all children with PWS. The Australian GH programme requires evaluation via PSG for airway obstruction within 12 months prior to the initiation of GH treatment and re-evaluation via PSG within the first 32 weeks of treatment for continuation. In New Zealand, a PSG or oximetry study is required prior to the initiation of GH therapy and 6–12 weeks after starting treatment in children under 2 years. Continuation is allowed if no adverse events attributable to GH are noted, without the explicit requirement for a repeat PSG.

The regulatory requirement to perform repeated sleep studies, in combination with the existence of a national PWS collaboration in Australia, has created an ideal opportunity to systematically analyse and evaluate the utility of repeated sleep studies in a large group of Australian children with PWS on GH therapy. Previous analysis of these showed a prevalence of OSA of 44% at baseline; however, the course of sleep disturbed breathing after the initiation of GH has not been evaluated to date. This study sets out to analyse the short-term relationships between the initiation of GH therapy in young children with PWS and central and obstructive sleep-disordered breathing using repeated PSG.

### Methods

#### Study design

This study was a retrospective observational study and patients were selected based on recorded administration of GH and availability of a baseline and follow-up PSG. If more than one PSG was performed before the initiation of GH, then only the last one performed closest to the date of GH initiation was considered and defined as the baseline PSG. Data were collected from seven specialised Australian PWS treatment clinics to describe clinical and PSG findings before and after the initiation of GH therapy, the first PSG for each child being performed between September 2001 and November 2017. A clinician-report questionnaire was administered using the Research Electronic Data Capture tool with each clinician being provided with a unique link for each of their patients who were eligible for this study. Specifically, data were provided to describe the child’s age, sex and genetic mutation group, other sleep-related diagnoses and treatments such as tonsillectomy and supplemental oxygen, and the date that GH therapy commenced. PSG was carried out in an attended in-laboratory setting in all cases and scoring was performed in accordance with standard scoring rules for children.

| Obstructive events in a small subgroup was mentioned in several studies. | 3 Our results offer support for the current advice to perform follow-up polysomnography in children with Prader-Willi syndrome after growth hormone is initiated. |
Obstructive and central AHIs were derived from pre- and post-GH PSG and clinical data at the time of PSG were noted including the child’s weight and whether there was need for respiratory support. Additionally, the obstructive AHI was categorised as normal (≤1/h), mild (1 < 5/h), moderate (5 < 10/h) and severe (≥10/h). The central AHI was categorised as normal (<5/h) or abnormal (≥5/h).

We included children who commenced GH therapy between January 2002 and March 2018.

### Statistical analyses

Continuous variables describing obstructive and central sleep-disturbed breathing before and after commencing GH therapy were compared with the Wilcoxon signed-rank test. We used non-parametric methods on account of clear departures from normality in the changes over time in the index scores. Categorised levels of obstructive and central AHI (normal/mild vs. moderate/severe) before and after commencing GH therapy were compared. Binomial confidence intervals for the proportion of children who developed moderate/severe OSA or central sleep apnoea (CSA) were calculated using the exact method of Clopper-Pearson. SPSS (V25) was used for all statistical analyses.

### Results

#### Participants

Obstructive and central AHI before and after commencing GH therapy was available for 112 children (50 female; median (range) age 1.9 (0–13.5) years), provided by seven clinics across five states in Australia. Genetic data showed that 32% had uniparental maternal disomy and 38% had a paternal deletion. GH was initiated in these patients between the years 2002 and 2018. Sixteen children had an adenoidectomy and/or tonsillectomy prior to the baseline sleep study.

- **Adenoidectomy and/or tonsillectomy prior to baseline PSG**
- **Respiratory support (oxygen or CPAP) during baseline study**

#### Table 1  Description of children at baseline PSG (n = 112)

| Clinical centre, State                        | N (%)          |
|-----------------------------------------------|----------------|
| Sydney Children’s Hospital, New South Wales   | 34 (30.4)      |
| Westmead Children’s Hospital, New South Wales | 24 (21.4)      |
| Queensland Children’s Hospital, Queensland    | 21 (18.8)      |
| Perth Children’s Hospital, Western Australia  | 15 (13.4)      |
| John Hunter Children’s Hospital, New South Wales | 10 (8.9)     |
| Women’s and Children’s Hospital, South Australia | 4 (3.6)     |
| Monash Children’s Hospital, Victoria          | 4 (3.6)        |

| Gender           | N (%)          |
|------------------|----------------|
| Male             | 62 (55.4)      |
| Female           | 50 (44.6)      |

| Mutation group             | N (%)          |
|---------------------------|----------------|
| Paternal deletion         | 43 (38.4)      |
| Uniparental maternal disomy | 36 (32.1)    |
| Imprinting disorder        | 3 (2.7)        |
| Unknown/other             | 30 (26.8)      |

| Age at start of GH (year) | Median (range) |
|--------------------------|----------------|
| 1.9 (0.1–13.5)           |                |

| Sleep-disordered breathing at baseline | Total AHI | Obstructive AHI | Central AHI | OSA severity | CSA |
|---------------------------------------|-----------|----------------|-------------|--------------|-----|
|                                       | 2.9 (0–52.6) | 0.43 (0–32.9) | 1.44 (0–50.0) | Normal | Absent | 73 (65.2) |
|                                       |            |                |             | Mild OSA    | Present | 36 (32.1) |
|                                       |            |                |             | Moderate OSA|        | 0 (0)     |
|                                       |            |                |             | Severe OSA  |        | 3 (2.7)   |

| OSA severity                  | Normal     | Mild OSA | Moderate OSA | Severe OSA | Absent | Present | N (%) |
|-------------------------------|------------|----------|--------------|------------|--------|---------|-------|
| N (%)                         | 73 (65.2)  | 36 (32.1)| 0 (0)        | 3 (2.7)    | 89 (79.5)| 23 (20.5) |

AHI, apnoea hypopnoea index; CSA, central sleep apnoea; GH, growth hormone; OSA, obstructive sleep apnoea; PSG, polysomnography.

#### Fig. 1  Flowchart study participants.

- **Included in analysis (N = 94)**
- **Excluded (N = 18)**
  - ≥2 years follow-up time (N = 1)
  - Adenoidectomy and/or tonsillectomy between studies (N = 3)
  - Respiratory support (N = 14)
The post-GH therapy PSG was conducted within 3 months in 54 (57.4%) of children, after three to 6 months in 26 (27.7%), after 6–9 months in 5 (5.3%), after 9–12 months in 6 (6.4%) and between 12 and 24 months after the initial PSG in 3 (3.2%) children. In total, 18 children were excluded from the comparative analysis (Fig. 1), the most common reason being that they were on some form of respiratory support, either at the time of baseline \((N = 13)\) or only at follow-up PSG \((N = 1)\). Because respiratory support, even supplemental oxygen, can have a profound effect on the scoring of both obstructive and central events, this was deemed reason for exclusion from the comparative analysis. The three children who were diagnosed with severe OSA

Table 2 Polysomnography data in children included in paired analysis \((n = 94)\)

|                           | PSG prior to commencing GH Median (range) | PSG after commencing GH Median (range) | \(P\) value |
|---------------------------|------------------------------------------|----------------------------------------|-------------|
| Age at PSG (years)        | 1.5 (0.1–13.2)                           | 2.2 (0.4–13.9)                         | n/a         |
| Time between 1st PSG and start of GH (months) | 3.4 (0.1–26.9)                           | -                                      | n/a         |
| Time between start of GH and follow-up PSG (months) | -                                        | 2.8 (0.6–23.6)                         | n/a         |
| Weight Z-score†           | -0.9 (--4.2 to 3.0)                      | -0.5 (--3.6 to 3.1)                    | 0.17        |
| Obstructive AHI           | 0.40 (0–4.9)                             | 0.50 (0–51.7)                          | 0.13        |
| Categories of OSA, \(N\) (\%) |                                            |                                        |             |
| Normal                    | 64 (86)                                  | 61 (65)                                |             |
| Mild OSA                  | 30 (32)                                  | 21 (22)                                |             |
| Moderate OSA              | 0 (0)                                    | 8 (9)                                  |             |
| Severe OSA                | 0 (0)                                    | 4 (4)                                  |             |
| Central AHI               | 1.4 (0–36.0)                             | 1.5 (0–32.2)                           | 0.20        |
| Categories of CSA, \(N\) (\%) |                                            |                                        |             |
| Absent                    | 76 (81)                                  | 80 (85)                                |             |
| Present                   | 18 (19)                                  | 14 (15)                                |             |

Of the \(n = 94\) children included in the comparative analysis, 11 children (12%) underwent adenoidectomy and/or tonsillectomy prior to baseline polysomnography. †For analysis including weight Z-scores, \(N = 85\) due to missing data in nine children. AHI, apnoea hypopnoea index; CSA, central sleep apnoea; GH, growth hormone; OSA, obstructive sleep apnoea; PSG, polysomnography.

Fig. 2 Change in obstructive AHI between paired sleep studies for children younger and older than 3 years, by the time from start of GH treatment to 2nd sleep study in months. Age groups: (a) Under 3 years and (b) over 3 years.
Based on the baseline PSG all received some form of OSA treatment between baseline study and GH initiation and were therefore excluded from the comparative analysis for this reason. In the comparative analysis, the remaining 94 children are included.

**Obstructive sleep apnoea**

In 94 children, the median (range) obstructive AHI was not significantly different between the two studies (0.4/h (0–4.9) prior to commencement of GH and 0.5/h (0–51.7) after GH \( (P = 0.13) \)). Twelve children \( (13\%; \, CI_{95\%} \, 7–21\%) \) changed category from normal/mild OSA to moderate/severe OSA (Table 2). Changes in the obstructive AHI were similar for children younger and older than 3 years and across different inter-testing intervals. However, there were some large changes over a short interval for the younger children (Fig. 2).

Eleven of the 94 children included in the comparative analysis underwent adenoidectomy and/or tonsillectomy prior to the baseline PSG. Restricting analysis to the 83 children who had not undergone previous surgery also did not show significant change in the median obstructive AHI before \( (0.3/h) \) and after GH initiation \( (0.5/h) \) \( (P = 0.14) \). Ten of these 83 children developed moderate/severe OSA \( (12\%; \, CI_{95\%} \, 6–21\%) \). In the small subgroup of 11 children with ENT surgery prior to the baseline PSG, 2 children \( (18\%) \) still changed from normal/mild to moderate/severe OSA, in both cases the surgery previously performed was adenotonsillectomy.

The median (range) Z-score for weight was \(-0.9 \, (–4.2 \, to \, +3.0) \) before GH, which increased to \(-0.5 \, (–3.6 \, to \, +3.1) \) after GH therapy \( (P = 0.17) \) (Table 2). Changes in obstructive AHI were not associated with changes in weight Z-score (Fig. 3). Also at follow-up, the absolute body mass index (BMI) score was not significantly associated with the probability of having moderate to severe OSA \( (P = 0.27, \, log \, binomial \, regression) \).

**Central sleep apnoea**

For 94 children, the median (range) central AHI did not change after commencement of GH (from 1.4/h \( (0–36.0) \) to 1.5/h \( (0–32.2) \), \( P = 0.20 \)). Eighteen children \( (19\%) \) had central sleep apnoea before commencing GH and 14 children \( (15\%) \) had central sleep apnoea after GH (Table 2). Changes in the central AHI were similar for children younger and older than 3 years at time of GH initiation (Fig. 4).

**Discussion**

In this Australian multicentre retrospective analysis of children with PWS using PSG before and after introduction of GH therapy, we found that the median obstructive AHI for the group did not increase significantly after the initiation of GH. However, 13\% \( (CI_{95\%} \, 7–21\%) \) of children with no or mild OSA at baseline developed moderate/severe OSA after the initiation of GH. Development of moderate–severe OSA could not be explained by changes in body weight and appeared to be more pronounced in the children under 3 years of age. In this cohort, we found no evidence of a change in central sleep apnoea after GH initiation.

There is ongoing controversy in the literature about the possible effects of GH on OSA. Several observational studies with
smaller sample sizes did not report significant worsening of sleep-disordered breathing 6 weeks to 6 months after the initiation of GH.13–16,21,22 The largest previous study (n = 50) reported an overall improvement in the respiratory disturbance index but, in line with our findings, the separate analysis of central and obstructive events revealed a significant increase in the proportion of children with an obstructive AHI >1/h from 6% at baseline to 22% at 1.5 months after GH initiation.16 Three other studies with sample sizes ranging from 15 to 30 reported no significant effect on the average frequency of obstructive events but reported a subset of children (n = 2 in each study) who had a sudden worsening of the obstructive AHI after GH initiation, prompting cessation of GH.13,15,22 It is possible that the lack of significant difference in obstructive AHI was a reflection of low power due to the small sample size. Most authors have reasoned that the risk of severe OSA developing in even a small subset of children justifies standard follow-up with PSG after GH initiation, and clinical consensus guidelines have also chosen this approach.18 Others however have stressed the absence of a consistent significant association between GH and OSA, suggesting that standard polysomnographic follow-up may not be indicated.17 Our study in combination with results by Berini et al.16 confirm that there is indeed an increase in obstructive events after introduction of GH in a significant subset of children, in our study leading to the development of moderate to severe OSA in 13% of children with PWS.

A recent randomised placebo controlled cross-over trial in 27 young adults with PWS on long-term GH therapy found no effect on the frequency of polysomnographic proven central or obstructive apnoeas with GH versus placebo.23 However, these findings cannot be generalised to our much younger population in whom GH is initiated for the first time. An important limitation in all previous studies of pre-school to school-aged children, including the current study, is the lack of a control group. This makes it impossible to attribute changes in the course of sleep-disordered breathing to GH therapy. The increase in obstructive events after GH might be explained by natural history as adenoid and tonsillar growth is maximal below the age of 5 years. Our data suggest that the increase in obstructive events was more pronounced in the group that started GH under the age of 3 years (median age 1.2 years). However, the increase in obstructive AHI appears to occur within the first months after the initiation of GH, and not to worsen with longer periods of follow-up (Fig. 2), as one would expect if the increase in obstructive events was based solely on natural history.

Previous studies have focussed mainly on the increased risk of obstructive breathing events after GH, based on the hypothesis that higher IGF-1 levels could induce tonsillar and adenoid tissue hyperplasia or retropharyngeal fluid accumulation, increasing the likelihood of upper airway collapse. In contrast, other authors have postulated that GH initiation could contribute to a decrease in obstructive events, potentially by improvements in muscle strength,24 improved CO2 responsiveness25 or improved body composition and lower BMI.14 For this last hypothesis, our data show little evidence, given there was no relation between changes in BMI and changes in obstructive AHI.

We found no significant associations between GH initiation and central sleep-disordered breathing in children with PWS. Several previous studies have suggested an improvement of sleep-disordered breathing after GH initiation due mainly to a reduction in central events.13,16,22 A potential positive effect of GH on central breathing drive may be explained by an improved ventilatory sensitivity to both carbon dioxide and oxygen in response to elevated IGF-1.25 Other studies however did not find a significant association between GH and central breathing events,14,15,21,23 in line with our findings. Discrepancies could be

Fig. 4 Change in central AHI between sleep studies for children younger and older than 3 years, by the time from start of GH treatment to 2nd sleep study in months. Age groups: (a) Under 3 years and (b) over 3 years.
explained by differences in the age of investigated children, as
the strongest effects on central sleep-disordered breathing have
previously been reported in the children under the age of 1 year.22
Up to eight central apnoeas per hour could be consid-
ered physiologic in infancy, with a natural reduction in frequency
continuing up to the second year of life.26 In children with PWS,
an increased prevalence of central sleep apnoea has been
reported both under the age of 2 years (43%), and later in child-
hood (5%).27 Logically, the power to detect a significant decrease
in central AHI will be higher during the peak incidence in
infancy, when the potential for improvement is highest. How-
ever, it is quite likely that at least part of the previously reported
beneficial effects after GH initiation is based on the favourable
natural course of central breathing events with age.

A key strength of the current study is the large sample size rec-
ruited from multiple institutions across Australia where baseline
and follow-up PSG is routinely performed as a prerequisite for
publicly funded GH. As such, we were able to exclude children
who received treatment for sleep-disordered breathing to avoid
confounding our analysis in relation to GH initiation. It should be
noted however, that this may have led to exclusion of cases with
a relatively high propensity to develop sleep-disordered
breathing.

Several limitations of this study need to be considered. As
noted, our study lacks a control group in whom no GH was
given. Therefore, changes in the course of sleep disturbed breath-
ing may reflect natural history rather than an effect of GH treat-
ment. Determining the separate effect of increasing age and GH
on the development of OSA would require a randomised con-
trolled trial with age matched patients, and such a trial is unlikely
to be undertaken given the established benefits of GH therapy in
PWS. Previous randomised controlled trials in pre-schoolers did
not show development of moderate–severe OSA in the control
arm over 6–12 months of follow-up in children with mild OSA at
baseline and so the change demonstrated in our study would be
unlikely based on natural history alone.28 Secondly, in this retro-
spective study, the timing of the follow-up PSG after the initia-
tion of GH was variable, ranging from 2 weeks up to 23 months.
Thirdly, sleep study scoring was done in multiple sleep laborato-
ries, spread out over a period of 20 years. Although scoring rules
may have changed over this period, the effect of this is minimised
by comparison of PSG before and after GH initiation using studies
from the same facility with a median timespan of 6 months in
between. All collaborating Australian sleep centres followed the
current American Academy of Sleep Medicine scoring manual
throughout the study period.29 Fourthly, although we aimed to
include all PWS patients treated with GH during the study period,
patient selection was dependent on the availability of repeated
PSG. The strict requirement for these studies in order to qualify
for GH treatment reimbursement increases the likelihood that
most eligible patients were included. However, selection may
have occurred if PSG was performed in outside the major public
hospitals included in our study group. We find it unlikely that
this selection would have resulted in any systematic selection bias
relevant to our findings. Finally, we did not find any cases of sud-
den death in our study population, but it should be clearly noted
that patient selection was based on the availability of baseline
and follow-up PSG, and not designed to screen for exceedingly
rare events.

What are the implications of our findings? There is little debate
about the efficacy of GH in children with PWS, particularly the
long-term benefits on linear growth and BMI.7 The relationship
between GH initiation and sleep-disturbed breathing, however,
remains strongly debated. To our knowledge, this is the largest
study to date investigating the course of sleep-related breathing
disorders in relation to GH initiation in children with PWS. Our
study provides evidence that a significant subset of children
develops moderate/severe OSA, particularly in the first months
after the initiation of GH. Although causality cannot be inferred,
our data offer support for the standard screening for development
of OSA within the first 6 months after GH initiation, as is cur-
rently standard practice in Australia.

Acknowledgements
This work is supported by a Prader-Willi Association USA 2016
Research Grant to CS Choong, D Caudri and A Wilson, a Perth
Children’s Hospital Foundation grant 2016 to D Caudri and a
Perth Children’s Hospital Foundation 2018 to CS Choong, J
Downs, D Caudri, H Leonard and G Nixon.

Ethical approval
This study was approved by the Human Research Ethics Commit-
tees at the Child and Adolescent Health Services (1739E) and
Children’s Health Queensland (HREC/17/QRCH/201) as the lead
state for the other sites in New South Wales, Victoria and South
Australia. Governance was confirmed at all sites.

References
1 Cassidy SB, Dykens E, Williams CA. Prader-Willi and Angelman syn-
dromes: Sister imprinted disorders. Am. J. Med. Genet. 2000; 97:
136–46.
2 Liotti T, Reid SM, Rowell MM. Prader-Willi syndrome in Victoria: Mor-
tality and causes of death. J. Paediatr. Child Health 2012; 48:
506–11.
3 Manzano AM, Loker J, Heinemann J, Loker C, Butler MG. Survival
trends from the Prader-Willi Syndrome Association (USA) 40-year mor-
tality survey. Genet. Med. 2018; 20: 24–30.
4 Arens R, Gozal D, Burrell BC et al. Arousal and cardiorespiratory
responses to hypoxia in Prader-Willi syndrome. Am. J. Respir. Crit.
Care Med. 1996; 153: 283–7.
5 Pacoricona Alfaro DL, Lemoine P, Ehlinger V et al. Causes of death in
Prader-Willi syndrome: lessons from 11 years’ experience of a
national reference center. Orphanet J. Rare Dis. 2019; 14: 238.
6 Yang A, Choi JH, Sohn YB et al. Effects of recombinant human growth
hormone treatment on growth, body composition, and safety in
infants or toddlers with Prader-Willi syndrome: A randomized, active-
controlled trial. Orphanet J. Rare Dis. 2019; 14: 216.
7 Scheeremeyer E, Hughes I, Harris M et al. Response to growth hor-
mone treatment in Prader-Willi syndrome: Auxological criteria versus
genetic diagnosis. J. Paediatr. Child Health 2013; 49: 1045–51.
8 Nordmann Y, Einholzer U, l’Allemand D, Mirjanic S, Markwalder C. Sud-
den death of an infant with Prader-Willi syndrome—Not a unique
case? Biol. Neonate 2002; 82: 139–41.
9 Van Vliet G, Deal CL, Crock PA, Robitaille Y, Oligny LL. Sudden death
in growth hormone-treated children with Prader-Willi syndrome.
J. Pediatr. 2004; 144: 129–31.
19 Vandeleur M, Davey MJ, Nixon GM. Are sleep studies helpful in children with Prader-Willi Syndrome prior to commencement of growth hormone therapy? J Pediatr. Child Health 2013; 49: 238–41.

20 Berry RB, Budhiraja R, Gottlieb DJ et al. Rules for scoring respiratory events in sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliverations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J. Clin. Sleep Med. 2012; 8: 597–619.

21 Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JO, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi Syndrome. J. Clin. Endocrinol. Metab. 2003; 88: 2206–12.

22 Khayat A, Narang I, Bin-Hasan S, Amin R, Al-Saleh S. Longitudinal evaluation of sleep disordered breathing in infants with Prader-Willi Syndrome. J. Pediatr. 2017; 102: 634–8.

23 Donze SH, de Weerdt AW, van den Bossche RAS, Joosten KFM, Hokken-Koelega ACS. Sleep-related breathing disorders in young adults with Prader-Willi syndrome: A placebo-controlled, cross-over GH trial. J. Clin. Endocrinol. Metab. 2019; 104: 3931–8.

24 Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi Syndrome. J. Pediatr. 2000; 137: 42–9.

25 Lindgren AC, Hellstrom LG, Ritzen EM, Milerad J. Growth hormone treatment increases CO2 response, ventilation and central inspiratory drive in children with Prader-Willi Syndrome. Eur. J. Pediatr. 1999; 158: 936–40.

26 McLaren AT, Bin-Hasan S, Narang I. Diagnosis, management and pathophysiology of central sleep apnea in children. Paediatr. Respir. Rev. 2019; 30: 49–57.

27 Cohen M, Hamilton J, Narang I. Clinically important age-related differences in sleep related disordered breathing in infants and children with Prader-Willi Syndrome. PLoS One 2014; 9: e101012.

28 Waters KA, Chawla J, Harris MA et al. Cognition after early tonsillectomy for mild OSA. Pediatrics 2020; 145: e20191450.